Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field
暂无分享,去创建一个
Torsten Haferlach | Peter Vandenberghe | Jason Gotlib | Peter Valent | T. Haferlach | K. Sotlar | A. Reiter | H. Simon | P. Valent | M. Mayerhofer | J. Gotlib | P. Vandenberghe | G. Gleich | J. Butterfield | P. Weller | M. Arock | H. Horny | G. Metzgeroth | Andreas Reiter | Bruce S Bochner | Andrzej Hellmann | Matthias Mayerhofer | Michel Arock | Georgia Metzgeroth | Sabine Cerny-Reiterer | B. Bochner | F. Roufosse | A. Klion | Hans-Uwe Simon | Joseph H Butterfield | Karl Sotlar | A. Hellmann | Peter F Weller | Hans-Peter Horny | Gerald J Gleich | Florence Roufosse | Kristin M Leiferman | Amy D Klion | K. Leiferman | S. Cerny‐Reiterer
[1] A. Straumann,et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense , 2008, Nature Medicine.
[2] G. Gleich. Mechanisms of eosinophil-associated inflammation. , 2000, The Journal of allergy and clinical immunology.
[3] P. Weller,et al. Functional extracellular eosinophil granules: novel implications in eosinophil immunobiology. , 2009, Current opinion in immunology.
[4] C. Bachert,et al. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. , 1997, Journal of immunology.
[5] P. Weller,et al. Practical approach to the patient with hypereosinophilia. , 2010, The Journal of allergy and clinical immunology.
[6] J. Denburg,et al. Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor. , 1985, Blood.
[7] D. Gilliland,et al. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. , 2006, Best practice & research. Clinical haematology.
[8] A. Kay,et al. Fc gamma and CD11/CD18 receptor expression on normal density and low density human eosinophils. , 1990, Immunology.
[9] S. Durham,et al. Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. , 1995, Journal of immunology.
[10] A. Tefferi. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1 , 2008, Journal of cellular and molecular medicine.
[11] M. van de Rijn,et al. Eotaxin Triggers Eosmophil-Selective Chemotaxis and Calcium Flux via a Distinct Receptor and Induces Pulmonary Eosinophilia in the Presence of Interleukin 5 in Mice , 1996, Molecular medicine.
[12] W. Hofmann,et al. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation , 2012, Leukemia.
[13] S. Schnittger,et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase‐II study , 2008, British journal of haematology.
[14] L. Boon,et al. Eosinophil differentiation in the bone marrow is inhibited by T cell-derived IFN-gamma. , 2010, Blood.
[15] F. Luscinskas,et al. Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules , 1991, The Journal of experimental medicine.
[16] A. Tefferi,et al. Eosinophilia: secondary, clonal and idiopathic , 2006, British journal of haematology.
[17] Gross Wl. Churg-Strauss syndrome: update on recent developments. , 2002, Current opinion in rheumatology.
[18] M. Vadas,et al. GM-CSF, IL-3 and IL-5: cross-competition on human haemopoietic cells. , 1992, Immunology today.
[19] B. Bochner,et al. Human eosinophils express two Siglec-8 splice variants. , 2002, The Journal of allergy and clinical immunology.
[20] D. Fabbro,et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. , 2003, Cancer cell.
[21] J. Boyce,et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. , 2004, The Journal of allergy and clinical immunology.
[22] R. Silver. Eosinophilia‐myalgia syndrome, toxic‐oil syndrome, and diffuse fasciitis with eosinophilia , 1992, Current opinion in rheumatology.
[23] L. Scapozza,et al. A novel FIP1L1‐PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome , 2009, Allergy.
[24] M. Capron. Eosinophils and parasites. , 1991, Annales de parasitologie humaine et comparee.
[25] A. Wardlaw,et al. Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils , 1991, The Journal of experimental medicine.
[26] Francesca Levi-Schaffer,et al. Inhibitory receptors on eosinophils: a direct hit to a possible Achilles heel? , 2007, The Journal of allergy and clinical immunology.
[27] G. Gleich,et al. Human eosinophil granule major basic protein and its novel homolog , 1998, Allergy. European Journal of Allergy and Clinical Immunology.
[28] D. Gilliland,et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias , 2004, Leukemia.
[29] R. Schleimer,et al. The effects of the potent glucocorticoid budesonide on adhesion of eosinophils to human vascular endothelial cells and on endothelial expression of adhesion molecules. , 1993, The Journal of pharmacology and experimental therapeutics.
[30] P. Valent,et al. Type beta transforming growth factors promote interleukin-3 (IL-3)- dependent differentiation of human basophils but inhibit IL-3-dependent differentiation of human eosinophils , 1992 .
[31] M. Rothenberg,et al. Origin, regulation and physiological function of intestinal oeosinophils. , 2008, Best practice & research. Clinical gastroenterology.
[32] R. Schleimer,et al. The role of adhesion molecules in human eosinophil and basophil recruitment. , 1994, The Journal of allergy and clinical immunology.
[33] H. Malech,et al. Early commitment to the eosinophil lineage by cultured human peripheral blood CD34+ cells: messenger RNA analysis. , 1996, The Journal of allergy and clinical immunology.
[34] A. B. Kay,et al. The Eosinophil in Infectious Diseases , 1974 .
[35] D. Rosing,et al. Cardiovascular manifestations of hypereosinophilic syndromes. , 2007, Immunology and allergy clinics of North America.
[36] M. Raffeld,et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. , 2010, The Journal of allergy and clinical immunology.
[37] B. Bochner,et al. Adhesion molecule antagonists: future therapies for allergic diseases? , 1993, The European respiratory journal.
[38] R. Schleimer,et al. Studies on the adhesive interaction between purified human eosinophils and cultured vascular endothelial cells. , 1988, Journal of immunology.
[39] P. Valent,et al. Developmental, Malignancy-Related, and Cross-Species Analysis of Eosinophil, Mast Cell, and Basophil Siglec-8 Expression , 2011, Journal of Clinical Immunology.
[40] M. Andersson,et al. Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis , 1999, Allergy.
[41] J. Hill,et al. Glucocorticoid receptors in normal human eosinophils: comparison with neutrophils. , 1981, The Journal of allergy and clinical immunology.
[42] R. Dummer,et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. , 1999, The New England journal of medicine.
[43] S. Wolff,et al. THE HYPEREOSINOPHILIC SYNDROME: Analysis of Fourteen Cases With Review of The Literature , 1975, Medicine.
[44] S. Stafford,et al. Transforming growth factor beta abrogates the effects of hematopoietins on eosinophils and induces their apoptosis , 1994, The Journal of experimental medicine.
[45] A. Grützkau,et al. Activation of the specific neurotrophin receptors TrkA, TrkB and TrkC influences the function of eosinophils , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[46] T. Nutman,et al. Evaluation and differential diagnosis of marked, persistent eosinophilia. , 2012, Seminars in hematology.
[47] D. Staunton,et al. αdβ2 Integrin Is Expressed on Human Eosinophils and Functions as an Alternative Ligand for Vascular Cell Adhesion Molecule 1 (VCAM-1) , 1998, The Journal of experimental medicine.
[48] J. Denburg. Microenvironmental influences on inflammatory cell differentiation , 1995, Allergy.
[49] P. Valent. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. , 2009, Blood reviews.
[50] M. Goldman,et al. Hypereosinophilic syndromes , 2007, Orphanet journal of rare diseases.
[51] W. Gross. Churg-Strauss syndrome: update on recent developments. , 2002, Current opinion in rheumatology.
[52] A. Kosar,et al. Eosinophilia in rheumatologic diseases: a prospective study of 1000 cases , 2004, Rheumatology International.
[53] M. Isobe,et al. Intercellular adhesion molecule‐1 on eosinophils is involved in eosinophil protein X release induced by cytokines , 1997, Immunology.
[54] B. Bain. Review: eosinophils and eosinophilic leukemia. , 2010, Clinical advances in hematology & oncology : H&O.
[55] P. Valent. The phenotype of human eosinophils, basophils, and mast cells. , 1994, The Journal of allergy and clinical immunology.
[56] M. Lotze,et al. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. , 2007, Journal of immunotherapy.
[57] H. Simon,et al. Eosinophil extracellular DNA traps in skin diseases. , 2011, The Journal of allergy and clinical immunology.
[58] T. Haferlach,et al. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers , 2007, Annals of Hematology.
[59] Kazuhiko Yamamoto,et al. Changing expression of IL-3 and IL-5 receptors in cultured human eosinophils. , 2003, Biochemical and biophysical research communications.
[60] P. Marynen,et al. FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib , 2009, Leukemia.
[61] Choon-Sik Park,et al. Interferon-γ Inhibits in vitro Mobilization of Eosinophils by Interleukin-5 , 2005, International Archives of Allergy and Immunology.
[62] D. Creamer,et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking , 2011, Clinical and experimental dermatology.
[63] S. Durham,et al. Eosinophils and eosinophil-associated cytokines in allergic inflammation. , 1997, International archives of allergy and immunology.
[64] Kenji Matsumoto,et al. Regulation of α4 integrin–mediated adhesion of human eosinophils to fibronectin and vascular cell adhesion molecule-1 , 1997 .
[65] L. Krupp,et al. Eosinophilia‐myalgia syndrome, toxic‐oil syndrome, and diffuse fasciitis with eosinophilia , 1995, Current opinion in rheumatology.
[66] K. Willard-Gallo,et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome , 2000, British journal of haematology.
[67] R. L. Barker,et al. The molecular biology of eosinophil granule proteins. , 1991, International archives of allergy and applied immunology.
[68] Peter Marynen,et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.
[69] A. Tefferi,et al. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.
[70] K. Ohta,et al. Expression and Function of Toll-Like Receptors in Eosinophils: Activation by Toll-Like Receptor 7 Ligand 1 , 2003, The Journal of Immunology.
[71] L. Guillevin,et al. Churg–Strauss syndrome: evidence for disease subtypes? , 2010, Current opinion in rheumatology.
[72] H. Kantarjian,et al. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia , 2007, Cancer.
[73] M. Feldmann,et al. T cells and lymphokines. , 1989, British medical bulletin.
[74] A. Tefferi. Modern Diagnosis and Treatment of Primary Eosinophilia , 2005, Acta Haematologica.
[75] A. Reiter,et al. Fibroblast Growth Factor Receptor and Platelet-Derived Growth Factor Receptor Abnormalities in Eosinophilic Myeloproliferative Disorders , 2008, Acta Haematologica.
[76] S. Georas,et al. Eosinophil transendothelial migration induced by cytokines. I. Role of endothelial and eosinophil adhesion molecules in IL-1 beta-induced transendothelial migration. , 1992, Journal of immunology.
[77] T. Schall,et al. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes , 1992, The Journal of experimental medicine.
[78] C. Feistritzer,et al. Expression and function of the vascular endothelial growth factor receptor FLT-1 in human eosinophils. , 2004, American journal of respiratory cell and molecular biology.
[79] A. Chase,et al. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. , 2007, Blood.
[80] N. Bovin,et al. Eosinophil-Selective Binding and Proapoptotic Effect in Vitro of a Synthetic Siglec-8 Ligand, Polymeric 6′-Sulfated Sialyl Lewis X , 2009, Journal of Pharmacology and Experimental Therapeutics.
[81] T. Colby,et al. Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. , 1992, The American journal of pathology.
[82] T. Fujisawa,et al. Inhibitory effect of transforming growth factor beta 1 on cytokine-enhanced eosinophil survival and degranulation. , 1995, International archives of allergy and immunology.
[83] B. Bain,et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. , 2002, The New England journal of medicine.
[84] W Newman,et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. , 1996, The Journal of clinical investigation.
[85] Y. Numagami,et al. Sinus thrombosis in idiopathic hypereosinophilic syndrome causing fatal cerebral haemorrhage , 2008, Journal of Clinical Neuroscience.
[86] D. Chi,et al. The role of human mast cell-derived cytokines in eosinophil biology. , 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[87] B. Bochner,et al. The surface phenotype of human eosinophils. , 2000, Chemical immunology.
[88] R. Schleimer,et al. Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment , 2001, Immunological reviews.
[89] T. Ganz,et al. Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. , 1989, Journal of immunology.
[90] J. Byström,et al. Plasminogen activator inhibitor‐2 (PAI‐2) in eosinophilic leukocytes , 2004, Journal of leukocyte biology.
[91] G. Gleich,et al. DEPOSITS OF EOSINOPHIL GRANULE PROTEINS IN CARDIAC TISSUES OF PATIENTS WITH EOSINOPHILIC ENDOMYOCARDIAL DISEASE , 1987, The Lancet.
[92] M. Goldman,et al. The hypereosinophilic syndrome revisited. , 2003, Annual review of medicine.
[93] R. Schleimer,et al. Comparison of human eosinophil and neutrophil ligands for P-selectin: ligands for P-selectin differ from those for E-selectin. , 1995, American journal of respiratory cell and molecular biology.
[94] E. Tabouret,et al. Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome. , 2011, Leukemia research.
[95] A. Vaglio,et al. Eosinophilic myocarditis in a patient with idiopathic hypereosinophilic syndrome: insights into mechanisms of myocardial cell death. , 2004, Human pathology.
[96] D. Gilliland,et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. , 2003, Blood.
[97] O. Götze,et al. The biologic role of interleukin-8: functional analysis and expression of CXCR1 and CXCR2 on human eosinophils. , 1999, Blood.
[98] B. Bochner. Siglec‐8 on human eosinophils and mast cells, and Siglec‐F on murine eosinophils, are functionally related inhibitory receptors , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[99] P. Murdock,et al. Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils. , 2000, The Journal of allergy and clinical immunology.
[100] J. Denburg. Hemopoietic progenitors and cytokines in allergic inflammation , 1998, Allergy.
[101] H. J. Wilkins,et al. Hypereosinophilic syndrome: An update , 2005, American journal of hematology.
[102] G. Walsh,et al. Advances in the immunobiology of eosinophils and their role in disease. , 1999, Critical reviews in clinical laboratory sciences.
[103] V. Cottin,et al. Churg-Strauss Syndrome , 2004, Seminars in respiratory and critical care medicine.
[104] C. Bizer,et al. Eosinophils Express Functional IL-13 in Eosinophilic Inflammatory Diseases1 , 2002, The Journal of Immunology.
[105] M. Vadas,et al. Interleukin-5, interleukin-3, and granulocyte-macrophage colony-stimulating factor cross-compete for binding to cell surface receptors on human eosinophils. , 1991, The Journal of biological chemistry.
[106] T. Graf,et al. Making Eosinophils Through Subtle Shifts in Transcription Factor Expression , 2002, The Journal of experimental medicine.
[107] M. Peters,et al. Ultrastructural study of eosinophils from patients with the hypereosinophilic syndrome: a morphological basis of hypodense eosinophils. , 1988, Blood.
[108] P. Proost,et al. Human monocyte chemotactic proteins-2 and 3 (MCP-2 and MCP-3) attract human eosinophils and desensitize the chemotactic responses towards RANTES. , 1994, Biochemical and biophysical research communications.
[109] S. Phipps,et al. Eosinophils: Biological Properties and Role in Health and Disease , 2008, Clinical and Experimental Allergy.
[110] B. Bain,et al. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. , 2007, Immunology and allergy clinics of North America.
[111] D. MacGlashan,et al. Macrophage-derived chemokine induces human eosinophil chemotaxis in a CC chemokine receptor 3- and CC chemokine receptor 4-independent manner. , 1999, The Journal of allergy and clinical immunology.
[112] A. B. Kay,et al. The eosinophil in infection diseases. , 1974, The Journal of infectious diseases.
[113] M. Ogawa,et al. Identification of pure and mixed basophil colonies in culture of human peripheral blood and marrow cells. , 1984, Blood.
[114] M. Rondoni,et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. , 2007, Blood.
[115] J. Sheikh,et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. , 2009, The Journal of allergy and clinical immunology.
[116] E. Baxter,et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. , 2003, Blood.
[117] G. Gleich,et al. What targeting eosinophils has taught us about their role in diseases. , 2010, The Journal of allergy and clinical immunology.
[118] A. Capron,et al. Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease , 1992, The Journal of experimental medicine.
[119] A. Klion. Hypereosinophilic syndrome: current approach to diagnosis and treatment. , 2009, Annual review of medicine.
[120] S. Woo,et al. Human Eosinophils Show Chemotaxis to Lymphoid Chemokines and Exhibit Antigen-Presenting-Cell-Like Properties upon Stimulation with IFN-γ, IL-3 and GM-CSF , 2008, International Archives of Allergy and Immunology.
[121] H. Kantarjian,et al. Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia , 2009, Clinical Cancer Research.
[122] P. Weller,et al. Eosinophils: structure and functions. , 1994, Current opinion in immunology.
[123] A. Macisaac,et al. Obstructive prosthetic mitral valve thrombosis in idiopathic hypereosinophilic syndrome: a case report and review of the literature. , 2006, The Journal of heart valve disease.
[124] T. Sugiura,et al. Chemotaxis of Human Peripheral Blood Eosinophils to 2-Arachidonoylglycerol: Comparison with Other Eosinophil Chemoattractants , 2006, International Archives of Allergy and Immunology.
[125] H. Simon,et al. Novel approaches to therapy of hypereosinophilic syndromes. , 2007, Immunology and allergy clinics of North America.
[126] H. Simon,et al. Eosinophilic disorders. , 2007, The Journal of allergy and clinical immunology.
[127] Lin Ying Liu,et al. Human Airway Eosinophils Respond to Chemoattractants with Greater Eosinophil-Derived Neurotoxin Release, Adherence to Fibronectin, and Activation of the Ras–ERK Pathway When Compared with Blood Eosinophils , 2010, The Journal of Immunology.
[128] H. Simon,et al. Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways. , 2011, The Journal of allergy and clinical immunology.
[129] Jiong Hu,et al. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. , 2008, Chinese medical journal.
[130] A. Reiter,et al. Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders , 2007, Haematologica.
[131] C. Ferland,et al. IL-16 Activates Plasminogen-Plasmin System and Promotes Human Eosinophil Migration into Extracellular Matrix via CCR3-Chemokine-Mediated Signaling and by Modulating CD4 Eosinophil Expression1 , 2004, The Journal of Immunology.
[132] P. Marynen,et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant , 2006 .
[133] T. Haferlach,et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. , 2012, The Journal of allergy and clinical immunology.
[134] D. Fabbro,et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[135] S. Ackerman,et al. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. , 2007, Immunology and allergy clinics of North America.
[136] H. Simon,et al. Refining the definition of hypereosinophilic syndrome. , 2010, The Journal of allergy and clinical immunology.
[137] R. Callard,et al. Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays , 1987, European journal of immunology.
[138] J. Parkin,et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. , 2008, The New England journal of medicine.
[139] H. Sarau,et al. Identification of Potent, Selective Non-peptide CC Chemokine Receptor-3 Antagonist That Inhibits Eotaxin-, Eotaxin-2-, and Monocyte Chemotactic Protein-4-induced Eosinophil Migration* , 2000, The Journal of Biological Chemistry.
[140] N. Talley,et al. Eosinophil infiltration and degranulation in normal human tissue , 1998, The Anatomical record.
[141] S. Okubo,et al. Clinical spectrum and endomyocardial biopsy findings in eosinophilic heart disease , 2005, Heart and Vessels.
[142] Christian J Wiedermann,et al. Expression and function of the angiopoietin receptor Tie-2 in human eosinophils. , 2004, The Journal of allergy and clinical immunology.
[143] C. Peschel,et al. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). , 2006, Blood.
[144] C. Preudhomme,et al. The severity of FIP1L1–PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus , 2007, Leukemia.
[145] Y. Levo,et al. Eosinophilia: A study of 100 hospitalized patients. , 2007, European journal of internal medicine.
[146] R. Schleimer,et al. The effects of glucocorticoids on human eosinophils. , 1994, The Journal of allergy and clinical immunology.
[147] P. Weller,et al. Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially , 2008, Journal of leukocyte biology.
[148] A. Minty,et al. Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine , 1994, The Journal of experimental medicine.
[149] Ji Ming Wang,et al. Recombinant human interleukin 5 is a selective eosinophil chemoattractant , 1989, European journal of immunology.
[150] Philipp Erben,et al. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. , 2011, Blood.
[151] J. Cools,et al. Five years since the discovery of FIP1L1–PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias , 2008, Leukemia.
[152] G. Superti-Furga,et al. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. , 2008, Experimental hematology.
[153] 牧野 荘平,et al. Eosinophils : biological and clinical aspects , 1993 .
[154] A. Donnenberg,et al. Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[155] A. Kay,et al. Eotaxin (CCL11) and Eotaxin-2 (CCL24) Induce Recruitment of Eosinophils, Basophils, Neutrophils, and Macrophages As Well As Features of Early- and Late-Phase Allergic Reactions Following Cutaneous Injection in Human Atopic and Nonatopic Volunteers1 , 2002, The Journal of Immunology.
[156] Xiangshan Fan,et al. [Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1]. , 2012, Zhonghua bing li xue za zhi = Chinese journal of pathology.
[157] M. K. Bach,et al. Activation of human eosinophils by platelet-derived growth factor. , 1992, International archives of allergy and immunology.
[158] A. Capron,et al. Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients: absence of detectable receptor correlates with resistance to corticotherapy. , 1989, Clinical and experimental immunology.
[159] J. Silver,et al. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. , 1992, Blood.
[160] J. Ring,et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. , 2003, The New England journal of medicine.
[161] H. Kita,et al. Transmigration of eosinophils through basement membrane components in vitro: synergistic effects of platelet-activating factor and eosinophil-active cytokines. , 1997, American journal of respiratory cell and molecular biology.
[162] D. Watkin,et al. REHABILITATION IN SCHIZOPHRENIA. , 1965, Lancet.
[163] H. Liapis,et al. Thrombotic microangiopathy associated with the hypereosinophilic syndrome. , 2005, Kidney international.
[164] R. Dixon,et al. Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro. , 2000, The Journal of allergy and clinical immunology.
[165] E. Belongia,et al. The eosinophilia-myalgia syndrome revisited. , 1996, The Journal of rheumatology.
[166] M. Seminario,et al. Expression and function of beta 1 integrins on human eosinophils. , 1997, Memorias do Instituto Oswaldo Cruz.
[167] U. Jäger,et al. Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy. , 2008, Leukemia research.
[168] B. Bain. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1 , 2010, Haematologica.
[169] P. Valent,et al. Interleukin-3 is a differentiation factor for human basophils. , 1989, Blood.
[170] G. Del Prete. Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy. , 1992, Allergy.
[171] Sandra A. Moore,et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo , 2005 .
[172] G. Gleich,et al. The biology of the eosinophilic leukocyte. , 1993, Annual review of medicine.
[173] K. Sotlar,et al. Eosinophil, basophil, and mast cell infiltrates in the bone marrow: crossing the boundaries of diagnosis , 2011 .
[174] E. Knol,et al. Comparison of human eosinophil and neutrophil adhesion to endothelial cells under nonstatic conditions. Role of L-selectin. , 1994, Journal of immunology.
[175] B. Bochner,et al. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. , 2003, Blood.
[176] J. Cools,et al. The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11) , 2010, Haematologica.
[177] F. Levi-Schaffer,et al. Cytokine generation by eosinophils. , 1994, The Journal of allergy and clinical immunology.
[178] H. Simon,et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. , 2006, The Journal of allergy and clinical immunology.
[179] B. Bochner. Systemic activation of basophils and eosinophils: markers and consequences. , 2000, The Journal of allergy and clinical immunology.
[180] A. J. Robinson,et al. Fluvastatin and lovastatin inhibit granulocyte macrophage–colony stimulating factor‐stimulated human eosinophil adhesion to inter‐cellular adhesion molecule‐1 under flow conditions , 2009, Clinical and Experimental Allergy.
[181] H. Kita. Eosinophils: multifaceted biological properties and roles in health and disease , 2011, Immunological reviews.